Expert Consensus on Vitamin B6 Therapeutic Use for Patients: Guidance on Safe Dosage, Duration and Clinical Management
This consensus statement highlights the importance of recognizing the benefits and potential risks of vitamin B6. While the therapeutic dosage of vitamin B6 can be beneficial to treat deficiency, excessive intake can lead to adverse effects. This statement emphasizes the need for individualized patient care considering factors such as medical history, lifestyle, and potential drug interactions. Further research is needed to establish clearer dosage guidelines, understand the mechanisms of vitamin B6-induced neurological side effects, and optimize patient outcomes.
Authors
- Fu Liong Hiew (ORCID: https://orcid.org/0000-0002-4708-3734)
- Kongkiat Kulkantrakorn (ORCID: https://orcid.org/0000-0001-7868-1385)
- Kitiyot Yotsombut (ORCID: https://orcid.org/0000-0001-5475-6944)
- Natalie Schellack (ORCID: https://orcid.org/0000-0001-9690-6285)
- Arman Sabet (ORCID: https://orcid.org/0000-0002-3469-6638)
- Jalal Nafach
Institutions
- Thammasat University (TH)
- Griffith University (AU)
- Chulalongkorn University (TH)
- Subang Jaya Medical Centre (MY)
- Diabetes UK (GB)
- University of Pretoria (ZA)
- Sunway University (MY)
Publication Details
- Journal
- Drug Healthcare and Patient Safety
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/dhps.s499941
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Procter and Gamble
- Biogen
- Alexion Pharmaceuticals
- CSL Behring
- Argenx
- Eisai
- Novo Nordisk
- Servier
- Ipsen
- Grifols
- Wörwag Pharma
- Terumo BCT
- Allergan